SK C&C-Korea Pharmaceutical Bio Association Collaborate to Build AI Drug Development Infrastructure

Promotion of Open Infrastructure Construction for AI Drug Development

[Asia Economy Reporter Jin-gyu Lee] SK C&C announced on the 12th that it has signed a Memorandum of Understanding (MOU) with the Korea Pharmaceutical and Bio-Pharma Manufacturers Association for "Building an Open Artificial Intelligence (AI) New Drug Development Infrastructure and Revitalizing the Ecosystem."

The two organizations plan to actively utilize SK C&C's AI, big data, and cloud technologies to promote the "AI New Drug Development Joint Project" between AI-specialized IT companies and pharmaceutical companies.

The AI New Drug Development Support Center (hereafter the Center) is focusing on creating an environment where domestic pharmaceutical and bio companies can use AI for new drug development by building AI new drug development infrastructure, supporting companies, and training experts. Centered around the Center, the two organizations plan to expand mutual cooperation measures such as ▲building an open AI new drug development infrastructure ▲securing big data for new drug development ▲sharing big data analysis technologies and related services ▲education for pharmaceutical companies.

SK C&C and the Association will also promote the creation of an AI new drug development ecosystem for domestic researchers. By collaborating with pharmaceutical companies, medical institutions, AI startups, and IT companies, they will secure AI new drug development services and introduce these services to domestic researchers for use in new drug development research.

Kim Hwa-jong, Director of the AI New Drug Development Support Center at the Korea Bio-Pharma Association, said, "Using artificial intelligence in the pharmaceutical and bio industry is becoming a necessity, not a choice," adding, "The Center will actively support pharmaceutical companies' AI new drug development by providing big data and cloud infrastructure."

Yoon Dong-jun, Head of SK C&C Healthcare Group, said, "We will develop optimal digital healthcare platforms and services tailored to domestic pharmaceutical and bio-specialized companies in cooperation with the Association," and added, "We will support the digital innovation of the Korean pharmaceutical and bio industry centered on the AI new drug development platform."

This content was produced with the assistance of AI translation services.